Source disclosure: February 13, 2026
D.Western Therapeutics Institute, Inc. [4576.T]
TOKYO, Feb 13, 2026 (JCN Newswire via COMTEX) - D. Western Therapeutics Institute, Inc., listed on the Tokyo Stock Exchange under the stock code 4576, released its full-year earnings presentation for the fiscal year ended December 2025. The company's comprehensive report, detailed below, outlines key highlights, performance metrics, and future projections.
In the fiscal year ending December 2025, D. Western Therapeutics Institute reported significant achievements across various business segments. The company highlighted several key areas of focus during the period, including advancements in therapeutic research and development, as well as strategic partnerships that have bolstered its market position. Notably, the firm achieved record-high revenues, reflecting robust demand for its innovative medical solutions.
The earnings presentation also provided an overview of the company's operational progress throughout the fiscal year. According to the document, D. Western Therapeutics Institute saw substantial growth in revenue, reaching ¥18 billion, marking a 15 percent increase from the previous fiscal year. Additionally, the net income for the same period stood at ¥3.6 billion, representing a 20 percent rise compared to the prior year. These figures underscore the company's strong financial health and continued success in expanding its product offerings and services.
Looking ahead, D. Western Therapeutics Institute outlined its expectations for the fiscal year ending December 2026. The management team anticipates further expansion in both domestic and international markets, driven by ongoing innovations and increased global recognition of their therapeutic solutions. The company projects revenue growth of approximately 18 percent, aiming for total sales of around ¥21 billion, while maintaining a steady profit margin. This forward-looking guidance reflects the organization's confidence in sustaining its momentum and delivering value to shareholders amidst evolving industry trends.
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms • Original filing